98 related articles for article (PubMed ID: 7682747)
1. Interferon alpha-2a treatment of patients with subfoveal neovascular macular degeneration. A pilot investigation.
Engler CB; Sander B; Koefoed P; Larsen M; Vinding T; Lund-Andersen H
Acta Ophthalmol (Copenh); 1993 Feb; 71(1):27-31. PubMed ID: 7682747
[TBL] [Abstract][Full Text] [Related]
2. Interferon alpha-2a for subfoveal neovascularization in age-related macular degeneration.
Poliner LS; Tornambe PE; Michelson PE; Heitzmann JG
Ophthalmology; 1993 Sep; 100(9):1417-24. PubMed ID: 8371932
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal interferon alpha-2b for the treatment of neovascular age-related macular degeneration: a pilot study.
Kertes PJ; Britton WA; Leonard BC
Can J Ophthalmol; 1997 Apr; 32(3):185-8. PubMed ID: 9131284
[No Abstract] [Full Text] [Related]
4. Treatment of choroidal neovascularization in age-related macular degeneration with interferon alpha-2a: a short term, nonrandomized pilot study.
Thoelen A; Menozzi M; Huber C; Messmer E
Ger J Ophthalmol; 1995 May; 4(3):137-43. PubMed ID: 7545047
[TBL] [Abstract][Full Text] [Related]
5. Interferon alpha-2a in the treatment of exudative senile macular degeneration.
Jaakkola A; Anttila PM; Immonen I
Acta Ophthalmol (Copenh); 1994 Oct; 72(5):545-9. PubMed ID: 7534027
[TBL] [Abstract][Full Text] [Related]
6. Interferon alfa-2a modifies the course of subfoveal and juxtafoveal choroidal neovascularisation.
Engler C; Sander B; Villumsen J; Lund-Andersen H
Br J Ophthalmol; 1994 Oct; 78(10):749-53. PubMed ID: 7528534
[TBL] [Abstract][Full Text] [Related]
7. Treatment of subfoveal choroidal neovascular membranes with systemic interferon-alpha 2a.
Loughnan MS; Heriot WJ; O'Day J
Aust N Z J Ophthalmol; 1992 Aug; 20(3):173-5. PubMed ID: 1280447
[TBL] [Abstract][Full Text] [Related]
8. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group.
Arch Ophthalmol; 1997 Jul; 115(7):865-72. PubMed ID: 9230826
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with interferon alfa-2a for exudative age-related macular degeneration.
Kirkpatrick JN; Dick AD; Forrester JV
Br J Ophthalmol; 1993 Dec; 77(12):766-70. PubMed ID: 7509185
[TBL] [Abstract][Full Text] [Related]
10. Interferon alfa-2a in the treatment of subfoveal choroidal neovascularization.
Thomas MA; Ibanez HE
Am J Ophthalmol; 1993 May; 115(5):563-8. PubMed ID: 7683842
[TBL] [Abstract][Full Text] [Related]
11. Interferon alfa-2a in the treatment of exudative age-related macular degeneration.
Lewis ML; Davis J; Chuang E
Graefes Arch Clin Exp Ophthalmol; 1993 Nov; 231(11):615-8. PubMed ID: 8258394
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of age-associated macular degeneration with interferon-alfa-2a].
Thölen A; Kain H; Messmer E
Ophthalmologe; 1993 Jun; 90(3):279-82. PubMed ID: 8334332
[TBL] [Abstract][Full Text] [Related]
13. Treatment of choroidal neovascularisation in age-related macular degeneration with interferon alfa-2a and alfa-2b.
Gillies MC; Sarks JP; Beaumont PE; Hunyor AB; McKay D; Kearns M; McClusky PJ; Sarks SH
Br J Ophthalmol; 1993 Dec; 77(12):759-65. PubMed ID: 7509184
[TBL] [Abstract][Full Text] [Related]
14. The treatment of choroidal neovascular membranes by alpha interferon. An efficacy and toxicity study.
Chan CK; Kempin SJ; Noble SK; Palmer GA
Ophthalmology; 1994 Feb; 101(2):289-300. PubMed ID: 7509472
[TBL] [Abstract][Full Text] [Related]
15. Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trial.
Lewis H; VanderBrug Medendorp S
Ophthalmology; 1997 Nov; 104(11):1847-51; discussion 1852. PubMed ID: 9373115
[TBL] [Abstract][Full Text] [Related]
16. Macular scatter ('grid') laser treatment of poorly demarcated subfoveal choroidal neovascularization in age-related macular degeneration. Results of a randomized pilot trial.
Bressler NM; Maguire MG; Murphy PL; Alexander J; Margherio R; Schachat AP; Fine SL; Stevens TS; Bressler SB
Arch Ophthalmol; 1996 Dec; 114(12):1456-64. PubMed ID: 8953976
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing visual acuity after photocoagulation for subfoveal choroidal neovascularization of exudative age-related macular degeneration.
Yuzawa M; Tamakoshi A; Ueha M; Kawakubo H; Nakajima M
Ophthalmology; 1996 Dec; 103(12):2037-41. PubMed ID: 9003337
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy for isolated occult subfoveal neovascularisation in age related macular degeneration: a pilot study.
Donati G; Soubrane D; Quaranta M; Coscas G; Soubrane G
Br J Ophthalmol; 1999 Jun; 83(6):646-51. PubMed ID: 10340969
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
Tao Y; Jonas JB
Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
